echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Wanchun Pharmaceutical's "Punabulin" reported to be listed in the priority review

    Wanchun Pharmaceutical's "Punabulin" reported to be listed in the priority review

    • Last Update: 2021-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 12, the official website of NMPA showed that the listing application of Wanchun Pharmaceutical's Pranabrin Concentrate Solution for Injection is planned to be included in the priority review and approval.


    Plinabulin is a small molecule of marine origin and an activator of guanine nucleotide exchange factor (GEF-H1).


    In addition, Plinabulin is a non-G-CSF drug that reverses the blocking formation of neutrophils in the bone marrow induced by docetaxel and maintains the level of neutrophils within the normal range.


    This listing application is based on positive data from the Phase 3 clinical trial PROTECTIVE-2 study.


    The results showed that the trial not only reached the primary endpoint, but also reached all key secondary endpoints.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.